TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35152464

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: TotalFill
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control (MTA, Biodentine, TotalFill)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 164
Study: 34514701

Group type: EXPERIMENTAL
Intervention: Idiopathic granulomatous mastitis with erythema nodosum (EN)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Idiopathic granulomatous mastitis only (control group)
Number of subjects: 86
Study: 35745198

Group type: EXPERIMENTAL
Intervention: 1 g/day bovine lactoferrin (bLF) for 3 weeks (T2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1 g/day bLF and 2.64 g/day active galactooligosaccharides (GOS) for 3 weeks (T3)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1 g/day bLF, 2.64 g/day GOS and 20 μg/day vitamin D for 3 weeks (T4)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 25
Study: 34604026

Group type: EXPERIMENTAL
Intervention: ReStOre program (exercise training, dietary counselling, and multidisciplinary education)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ReStOre program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 37
Study: 34154913

Group type: COMPARATOR
Intervention: Pre-QI (2017) survey respondents
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Post-QI (2019) survey respondents
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: First-time respondents in 2019
Number of subjects: 94
Study: 34421257

Group type: EXPERIMENTAL
Intervention: Check pyeloscopic percutaneous nephrolithotomy (CP‐PCNL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional percutaneous nephrolithotomy (C‐PCNL)
Number of subjects: 100
Study: 33101444

Group type: EXPERIMENTAL
Intervention: Qingshen granules (three times daily for 12 weeks)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Conventional Western medical therapy (control group)
Number of subjects: 282
Study: 35716319

Group type: EXPERIMENTAL
Intervention: DE-089C (long-acting diquafosol ophthalmic solution), administered three times daily for 4 weeks
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo ophthalmic solution, administered three times daily for 4 weeks
Number of subjects: 337
Study: 34626550

Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 440

Group type: COMPARATOR
Intervention: placebo plus paclitaxel
Number of subjects: 440
Study: 33263641

Group type: EXPERIMENTAL
Intervention: Heart failure (HF) patients during active postural maneuver (APM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: COPD-HF patients during active postural maneuver (APM)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Heart failure (HF) patients during respiratory sinus arrhythmia maneuver (RSA-M)
Number of subjects: 41

Group type: COMPARATOR
Intervention: COPD-HF patients during respiratory sinus arrhythmia maneuver (RSA-M)
Number of subjects: 41
Study: 35942886

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) for one hour daily from birth until postnatal week five
Number of subjects: 116

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 116
Study: 32783395

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 215

Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Ala carriers
Number of subjects: 215

Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Pro12Ala polymorphism
Number of subjects: 215
Study: 33248059

Group type: EXPERIMENTAL
Intervention: NSTE-MI
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: LBBB-MI
Number of subjects: 665

Group type: COMPARATOR
Intervention: ECG presentation
Number of subjects: 665
Study: 33742266

Group type: EXPERIMENTAL
Intervention: Functional Power Training (FPT) program, 12-week duration, 2 sessions per week of 60 minutes each
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual activities at senior centers
Number of subjects: 61
Study: 33096291

Group type: EXPERIMENTAL
Intervention: Exposure therapy + PE‐FMR
Number of subjects: 166

Group type: COMPARATOR
Intervention: Exposure therapy alone
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Exposure therapy + DE
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Exposure therapy + PE‐FMR + DE
Number of subjects: 166
Study: 36091150

Group type: EXPERIMENTAL
Intervention: Combined (preoperative calcitriol and calcium)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control (no preoperative intervention)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Calcium only (preoperative calcium only)
Number of subjects: 172
Study: 33082056

Group type: EXPERIMENTAL
Intervention: Low HDL-cholesterol levels (low-HDLc)
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Atherogenic dyslipidemia (AD)
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Independent factors associated with low HDLc
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Major factors associated with low HDLc and AD
Number of subjects: 6588
Study: 35995728

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 32725475

Group type: EXPERIMENTAL
Intervention: Modified suturing technique (group A)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Standard technique (group B)
Number of subjects: 257
Study: 35706488

Group type: EXPERIMENTAL
Intervention: Active symptom control with oral vinorelbine (ASC + vinorelbine)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Active symptom control (ASC)
Number of subjects: 154
Study: 34506512

Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 137

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 137
Study: 33431242

Group type: EXPERIMENTAL
Intervention: Diabetes medication-taking behavior
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Medication-taking behavior
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Hurried Communication
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Diabetes distress
Number of subjects: 1270
Study: 35772139

Group type: EXPERIMENTAL
Intervention: Musicotherapy combined with cognitive behavioral intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (blank control, no intervention)
Number of subjects: 120
Study: 34106303

Group type: EXPERIMENTAL
Intervention: Subcutaneous pertuzumab and trastuzumab (PH FDC SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous pertuzumab and trastuzumab
Number of subjects: 0
Study: 36351465

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg daily
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190

Group type: COMPARATOR
Intervention: Fish oil
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cinnamon
Number of subjects: 190

Group type: COMPARATOR
Intervention: Garlic
Number of subjects: 190

Group type: COMPARATOR
Intervention: Turmeric
Number of subjects: 190

Group type: COMPARATOR
Intervention: Plant sterols
Number of subjects: 190

Group type: COMPARATOR
Intervention: Red yeast rice
Number of subjects: 190
Study: 33412260

Group type: EXPERIMENTAL
Intervention: 74 Gy/37 fractions (Fr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 Gy/20 Fr
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 57 Gy/19 Fr
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion of IBD/diverticular disease as a DMF
Number of subjects: 0

Group type: COMPARATOR
Intervention: No DMF vs DMF models for stool frequency G2+
Number of subjects: 0

Group type: COMPARATOR
Intervention: No DMF vs DMF models for proctitis G1+
Number of subjects: 0
Study: 32725178

Group type: EXPERIMENTAL
Intervention: Improving Pain During Addiction Treatment (ImPAT)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Supportive Psychoeducational Control (SPC)
Number of subjects: 510
Study: 35038412

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance stress myocardial perfusion imaging (CMR‐MPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional functional imaging
Number of subjects: 0
Study: 32761160

Group type: EXPERIMENTAL
Intervention: Candesartan (up to 32 mg once daily)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Lisinopril (up to 40 mg once daily)
Number of subjects: 176
Study: 36175963

Group type: EXPERIMENTAL
Intervention: Enhanced monitoring and feedback (EMF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2-day workshop
Number of subjects: 72

Group type: COMPARATOR
Intervention: Internal facilitation
Number of subjects: 72

Group type: COMPARATOR
Intervention: External facilitation
Number of subjects: 72
Study: 34769851

Group type: EXPERIMENTAL
Intervention: Aerobic gymnastics (80 min/d, 5 d/wk for 8 months)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Aerobic gymnastics
Number of subjects: 102
Study: 33271502

Group type: EXPERIMENTAL
Intervention: Self-selected condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Imposed condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional condition
Number of subjects: 15
Study: 34152031

Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fulvestrant alone (Control)
Number of subjects: 0
Study: 33357803

Group type: EXPERIMENTAL
Intervention: Education program and traditional music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 32727336

Group type: EXPERIMENTAL
Intervention: Antithyroid therapy (thioamides and/or surgical therapy)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Surgical therapy (group 2, n=9)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Medical therapy (group 1, n=62)
Number of subjects: 71
Study: 32615145

Group type: EXPERIMENTAL
Intervention: Connectedness to Nature (CN) intervention (10 sessions of a family-based programme)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Connectedness to Nature (CN) intervention
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control Group (CG) receiving only government's health recommendations
Number of subjects: 241
Study: 35332374

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (PPI) with standard care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 33902333

Group type: EXPERIMENTAL
Intervention: UC with acupuncture
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: UC with pain counseling
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: UC with acupuncture and pain counseling
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 11
Study: 35477992

Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (UFH)
Number of subjects: 514
Study: 33668050

Group type: EXPERIMENTAL
Intervention: MMs (15 micronutrients including IFA)
Number of subjects: 1599

Group type: COMPARATOR
Intervention: FA (folic acid only)
Number of subjects: 1599
Study: 34124856

Group type: EXPERIMENTAL
Intervention: Ketogenic diet app with breath acetone biofeedback
Number of subjects: 155

Group type: COMPARATOR
Intervention: Calorie-restricted low-fat diet app
Number of subjects: 155
Study: 35810277

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CRO) 1 g IV + Doxycycline (DOX)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cefixime (CFM) 800 mg oral + Doxycycline (DOX)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CRO) + Doxycycline (DOX)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cefixime (CFM) + Doxycycline (DOX)
Number of subjects: 125
Study: 33540413

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: EuroQol 5-dimensions
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Short-form 6-dimension medical outcome questionnaire
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Euro-thermometer visual analog scale
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Time trade-off
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Standard gamble
Number of subjects: 208
Study: 35483674

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg daily
Number of subjects: 60
Study: 34551811

Group type: EXPERIMENTAL
Intervention: Nudge
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nudge+
Number of subjects: 32
Study: 35598852

Group type: EXPERIMENTAL
Intervention: CT/CT angiography
Number of subjects: 190
Study: 33957004

Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds oil (2.5 ml twice daily for 8 weeks)
Number of subjects: 55
Study: 32951358

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg or 10 mg/kg for body weight <30 kg; 8 mg/kg for body weight ≥30 kg) administered intravenously every 4 weeks for 16 weeks, followed by random assignment to tocilizumab or placebo.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (in part 2 of the trial).
Number of subjects: 188
Study: 35461890

Group type: EXPERIMENTAL
Intervention: Tunnel endoscopic submucosal dissection (T-ESD)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (C-ESD)
Number of subjects: 152
Study: 34063304

Group type: EXPERIMENTAL
Intervention: HIIT + NT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 34433379

Group type: EXPERIMENTAL
Intervention: VaLiANT intervention (group-based intervention for valued living)
Number of subjects: 8
Study: 32468669

Group type: EXPERIMENTAL
Intervention: Health belief model-based education and acupressure
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Health belief model-based education only
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 163
Study: 34597729

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 (VDZ)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 plus an additional dose at week 10 (VDZ + wk10)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both vedolizumab regimens
Number of subjects: 32
Study: 34406312

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) users
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Prophylactic-dose LMWH users
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Intermediate-dose LMWH users (based on biomarkers)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Nonusers of anticoagulants
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: All LMWH users
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Major hemorrhage
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Thromboembolism
Number of subjects: 690
Study: 33655601

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35065602

Group type: EXPERIMENTAL
Intervention: Two-handed (TH) ECC
Number of subjects: 35

Group type: COMPARATOR
Intervention: One-handed (OH) ECC
Number of subjects: 35
Study: 32757418

Group type: EXPERIMENTAL
Intervention: Sweet-tasting solution
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sterile water (Control)
Number of subjects: 56
Study: 35040873

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33118688

Group type: EXPERIMENTAL
Intervention: Prediction model based on traditional risk factors, biomarkers, and variabilities in fasting plasma glucose, HbA1c, and blood pressure.
Number of subjects: 9692

Group type: EXPERIMENTAL
Intervention: Prediction model for expanded cardiovascular-specific mortality.
Number of subjects: 9692
Study: 35285143

Group type: EXPERIMENTAL
Intervention: Electronic reminder (alert group)
Number of subjects: 13000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Alert group
Number of subjects: 13000
Study: 34271362

Group type: EXPERIMENTAL
Intervention: Duloxetine (40 mg BID) + innovative pelvic floor muscle training (iPFMT) with lumbopelvic stabilization
Number of subjects: 158

Group type: COMPARATOR
Intervention: Oral duloxetine treatment (40 mg BID)
Number of subjects: 158
Study: 32524641

Group type: EXPERIMENTAL
Intervention: Selective recruitment protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly selected cohorts
Number of subjects: 0
Study: 34342023

Group type: EXPERIMENTAL
Intervention: Oversized postcard intervention promoting water testing with a free water test offer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oversized postcard intervention promoting water testing without a free water test offer
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 0
Study: 34019549

Group type: EXPERIMENTAL
Intervention: Op/eds defending impartiality of truth-seekers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video op/ed exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text op/ed availability
Number of subjects: 0
Study: 32253184

Group type: EXPERIMENTAL
Intervention: Bimekizumab 16 mg
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Bimekizumab 64 mg
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Bimekizumab (all doses)
Number of subjects: 303
Study: 35635233

Group type: EXPERIMENTAL
Intervention: FIT-based screening (invited group)
Number of subjects: 897812

Group type: EXPERIMENTAL
Intervention: FIT-based screening (participating group)
Number of subjects: 897812

Group type: EXPERIMENTAL
Intervention: FIT-based screening (male participants aged 60-71 years)
Number of subjects: 897812

Group type: COMPARATOR
Intervention: Not-yet-invited group (control)
Number of subjects: 897812
Study: 32533243

Group type: EXPERIMENTAL
Intervention: ANODAL tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: CATHODAL tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: SHAM tDCS
Number of subjects: 14
Study: 35379598

Group type: EXPERIMENTAL
Intervention: 4 mg/kg intravenous tocilizumab (Group 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 8 mg/kg intravenous tocilizumab (Group 2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both doses of intravenous tocilizumab
Number of subjects: 37
Study: 33454995

Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined Oral Contraceptives (COCs)
Number of subjects: 0
Study: 32374352

Group type: EXPERIMENTAL
Intervention: Face-aging mobile app Sunface intervention
Number of subjects: 1573

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1573
Study: 34518968

Group type: EXPERIMENTAL
Intervention: Hypothermia (controlled temperature management to 35°C prior to dura opening followed by 33°C for 48 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normothermia (37°C)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 32
Study: 34044355

Group type: EXPERIMENTAL
Intervention: I-Gel®
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bag-valve-mask
Number of subjects: 23
Study: 35522981

Group type: EXPERIMENTAL
Intervention: Continuous moderate‐intensity exercise (CMIE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High‐intensity interval exercise (HIIE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CMIE and HIIE
Number of subjects: 20
Study: 35840980

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) goggles and headphones during plaster removal or replacement
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 270
Study: 33792726

Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Number of subjects: 92

Group type: COMPARATOR
Intervention: Flexion exercises
Number of subjects: 92
Study: 32399799

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) facilitated conversation and Advance directive completion (n=155 dyads)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group (n=68 dyads) with Developmental/relationship history and Nutrition/exercise tips
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP)
Number of subjects: 449
Study: 35046189

Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation (IMF) screw therapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (intraarticular saline injection)
Number of subjects: 300
Study: 32345561

Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl
Number of subjects: 186

Group type: COMPARATOR
Intervention: Intravenous ketorolac
Number of subjects: 186
Study: 33186393

Group type: EXPERIMENTAL
Intervention: 6 x 30 s Wingate sprints in hypoxia (3,000 m)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 6 x 30 s Wingate sprints at sea-level and up to 2,150 m
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 x 30 s Wingate sprints at 2,150 m
Number of subjects: 10
Study: 36026477

Group type: EXPERIMENTAL
Intervention: Refined maize porridge with [57Fe]-labeled crickets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Refined maize porridge with unlabeled crickets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference meal (refined maize porridge with [58Fe]SO4)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unrefined maize porridge with crickets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unrefined maize porridge with [58Fe]SO4
Number of subjects: 20
Study: 33757503

Group type: EXPERIMENTAL
Intervention: Mental Training
Number of subjects: 67

Group type: COMPARATOR
Intervention: See One, Do One
Number of subjects: 67
Study: 32173375

Group type: EXPERIMENTAL
Intervention: gp120 trimers bound to BLPs delivered via intranasal (i.n.) drip
Number of subjects: 0
Study: 33131314

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP <120 mm Hg)
Number of subjects: 4678